Lutathera(177Lu-DOTATATE)上市后安全性评价:基于FDA不良事件报告系统的药物警戒分析
本研究利用FAERS数据库2019年第四季度至2024年第三季度的数据,对Lutathera(177Lu-DOTATATE)相关不良事件进行回顾性药物警戒分析,共纳入4284份报告,中位发病时间为113.5天,相关不良事件死亡率高达31.2%,在13个系统器官分类中检出显著信号,以内分泌疾病信号最突出。
要点
- 共分析4284份Lutathera相关不良事件报告,中位发病时间113.5天,死亡率达31.2%。
- 在13个系统器官分类中检出显著信号,内分泌疾病信号最突出。
- 主要首选术语包括非特异性疾病(IC025:5.92)、类癌综合征(IC025:5.69)和类癌危象(IC025:5.62)。
核心结论
- 研究利用真实世界数据识别出Lutathera相关的多个风险信号,为其合理使用提供额外证据。
- 作者指出,由于FAERS数据库的固有局限性,需进一步研究验证这些发现。
研究设计与样本
- 回顾性药物警戒分析,使用FAERS数据库2019年第四季度至2024年第三季度的数据。
- 采用病例/非病例方法,通过报告比值比和信息成分(IC)进行不成比例分析以评估不良事件信号。
- 共纳入4284份与Lutathera相关的不良事件报告,分析了患者人口学特征、不良事件发生时间和系统器官分类涉及情况。
主要发现
- Lutathera相关不良事件的中位发生时间为113.5天。
- Lutathera相关不良事件死亡率高达31.2%。
- 在13个系统器官分类和多个首选术语中检出统计学显著信号,其中内分泌疾病类别的信号最突出。
- 主要首选术语包括非特异性疾病(IC025:5.92)、类癌综合征(IC025:5.69)和类癌危象(IC025:5.62)。
- 报告了药品说明书中未记载的首选术语,如脑炎、肠缺血和弥散性血管内凝血。
局限性
- 作者指出,由于FAERS数据库的固有局限性,需进一步研究验证这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lutathera, a key therapy for gastroenteropancreatic neuroendocrine tumors, has demonstrated efficacy, but its real-world safety profile remains unclear. This study aims to conduct a comprehensive analysis of the adverse events (AEs) associated with Lutathera using FDA Adverse Event Reporting System (FAERS) data. PATIENTS AND METHODS: A retrospective pharmacovigilance analysis was conducted using FAERS data from Q4 2019 to Q3 2024. AE reports involving Lutathera were identified, and a case/non-case approach was employed to evaluate AE signals using disproportionality analysis methods, including the reporting odds ratio and information component (IC). Patient demographics, time to AE onset, and system organ class (SOC) involvement were analyzed. RESULTS: After data processing, a total of 4284 AE reports associated with Lutathera were analyzed. The median time to AE onset was 113.5 days. Lutathera-related AEs exhibited a notably high mortality rate, reaching as much as 31.2%. Statistically significant signals were detected across 13 SOCs and multiple preferred terms (PTs). Among the SOCs, the most pronounced signals were observed in the category of endocrine disorders. The leading PTs included nonspecific disorders (IC 025 : 5.92), carcinoid syndrome (IC 025 : 5.69), and carcinoid crisis (IC 025 : 5.62). Moreover, several PTs not documented in the drug's labeling were reported, such as encephalitis, intestinal ischemia, and disseminated intravascular coagulation. CONCLUSIONS: Our study utilized real-world data to identify multiple risk signals associated with Lutathera, providing additional evidence to support its rational use. However, due to the inherent limitations of the FAERS database, further research is warranted to validate these findings.
引用
- Chen H, Ma J. Post-marketing Safety Evaluation of Lutathera ( 177 Lu-DOTATATE) : A Pharmacovigilance Analysis of FDA Adverse Event Reporting System. Clin Nucl Med. 2025. PMID: 40310018. doi:10.1097/RLU.0000000000005861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。